LH - Laboratory Corporation of America Holdings
| Previous Close | 171.11 |
| Open | 171.17 |
| Bid | 173.19 x 1100 |
| Ask | 173.27 x 800 |
| Day's Range | 170.91 - 173.80 |
| 52 Week Range | 119.38 - 178.44 |
| Volume | 387,128 |
| Avg. Volume | 632,028 |
| Market Cap | 16.912B |
| Beta (3Y Monthly) | 0.99 |
| PE Ratio (TTM) | 20.44 |
| EPS (TTM) | 8.48 |
| Earnings Date | Oct 22, 2019 - Oct 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1994-03-29 |
| 1y Target Est | 189.18 |
- Business Wire
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest
LabCorp® (LH) announced today that for the period of Sept. 11, 2019 to March 10, 2020, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended Sept. 6, 2018, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $2.81 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is Feb. 21, 2020. The payment of contingent cash interest is expected to be made on March 9, 2020.
- Business Wire
Covance Unveils New R&D Center in Shanghai
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that its Covance Drug Development business celebrated the opening of its new R&D Center in Shanghai, China, which is now its largest facility in the Asia Pacific region.
- Simply Wall St.
These 4 Measures Indicate That Laboratory of America Holdings (NYSE:LH) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Zacks
LabCorp's Covance Launches Laboratory Data Management Service
LabCorp (LH) expands service portfolio through Covance's data management portal.
- Business Wire
LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference
LabCorp® (LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference. LabCorp’s presentation is planned for Monday, Sept. 9, 2019 at 9:55 a.m. ET. A live audio webcast will be available via the Company website at www.LabCorp.com and archived for replay.
- Business Wire
Covance Launches Laboratory Data Management Functional Service Provider for Pharmaceutical and Biotechnology Customers
Program Expands the Company’s Growing and Unique FSPx Capabilities
- American City Business Journals
LabCorp joins in $17.5M round for Cambridge diagnostic startup Boston Microfluidics
Boston Microfluidics currently offers two tests for lipids and A1C levels, but CEO Brandon Johnson said the current tool could handle up to 13 tests and potentially more.
- Zacks
LabCorp (LH) Down 3.4% Since Last Earnings Report: Can It Rebound?
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Can Value Investors Pick Laboratory Corporation (LH) Stock?
Let's see if Laboratory Corporation (LH) stock is a good choice for value-oriented investors right now from multiple angles.
- Simply Wall St.
Is Laboratory Corporation of America Holdings (NYSE:LH) Potentially Undervalued?
Let's talk about the popular Laboratory Corporation of America Holdings (NYSE:LH). The company's shares received a lot...
- Thomson Reuters StreetEvents
Edited Transcript of LH earnings conference call or presentation 25-Jul-19 1:00pm GMT
Q2 2019 Laboratory Corporation of America Holdings Earnings Call
- Motley Fool
What You'll Want to Know About LabCorp's Q2 Earnings Results
The laboratory services giant posted mixed results in the second quarter and narrowed its full-year 2019 outlook.
Motley FoolLaboratory Corp Of America Holdings (LH) Q2 2019 Earnings Call Transcript
LH earnings call for the period ending June 30, 2019.
- Zacks
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
- Zacks
LabCorp (LH) Tops Q2 Earnings Estimates
LabCorp (LH) delivered earnings and revenue surprises of 1.03% and -0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Medical Products' Earnings Roster for Jul 25: SYK, BAX & More
Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.
- Simply Wall St.
Does Laboratory Corporation of America Holdings's (NYSE:LH) P/E Ratio Signal A Buying Opportunity?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- Zacks
Will LabCorp's (LH) Q2 Earnings Gain From Overall Growth?
Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.
- Zacks
LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
LH vs. CNMD: Which Stock Is the Better Value Option?
LH vs. CNMD: Which Stock Is the Better Value Option?
- TechCrunch
Another 2.2 million patients affected by AMCA data breach
Another clinical lab ensnared in the AMCA data breach has come forward. Clinical Pathology Laboratories (CPL) says 2.2 million patients may have had their names, addresses, phone numbers, dates of birth, dates of service, balance information and treatment provider information stolen in the previously reported breach. Another 34,500 patients had their credit card or banking information compromised.
- GuruFocus.com
Laboratory Corp Of America Holdings (LH) CFO, EVP Glenn A Eisenberg Sold $983,260 of Shares
CFO, EVP of Laboratory Corp Of America Holdings (LH) Glenn A Eisenberg sold 5,563 shares of LH on 07/08/2019 at an average price of $176.75 a share.
- Markit
See what the IHS Markit Score report has to say about Laboratory Corporation of America Holdings.
Laboratory Corporation of America Holdings NYSE:LHView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for LH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.64 billion over the last one-month into ETFs that hold LH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. LH credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
